Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiation in Locally Advanced Pancreatic Cancer
NCT00089024Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Feb 2004
- Primary completion
- Jan 2010
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, fluorouracil, folinic acid and oxaliplatin in pancreatic cancer (PC), sponsored by University of Nebraska. Primary endpoints: Surgical Exploration Rate at 10 weeks and Incidence of Grade 3-4 Toxicity at 24 weeks. Started Feb 2004; status: completed.
02
Drugs
gemcitabinefluorouracilfolinic acidoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00089024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089024.